Overview
Swedish medical tech firm's Q4 net sales beat analyst expectations
Organic growth driven by recovery in lung and strong liver and kidney performance
Company signed partnership with Perfusion Solution Inc to expand U.S. services
Outlook
Xvivo plans to expand U.S. operations in 2026
Company prepares for 2027 product launch of Heart Assist Transport
Xvivo sees strong development in liver and kidney segments
Result Drivers
ABDOMINAL BUSINESS - Co reported 30% sales growth in the Abdominal business area in local currencies
SERVICES DECLINE - Services segment saw a 21% decrease due to reduced organ recovery volumes
CURRENCY IMPACT - Net profit affected by currency effects in cash and cash equivalents
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
SEK 226.10 mln
SEK 210.77 mln (3 analysts)
Q4 EPS
SEK 1.01
Q4 Net Income
SEK 31.60 mln
Q4 EBIT
SEK 36.80 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Xvivo Perfusion AB is SEK310.00, about 41.7% above its January 26 closing price of SEK218.80
The stock recently traded at 59 times the next 12-month earnings vs. a P/E of 40 three months ago
Press Release: ID:nMFN2LNDsf
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)